Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 225

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9C
Chunk 225
---
 on a number of
factors, including:

    ●
    The
    nature, responsibilities and duties of the officer’s position;

    ●
    The
    officer’s expertise, demonstrated leadership ability and prior performance;

    ●
    The
    officer’s salary history and total compensation, including annual cash bonuses and long-term incentive compensation; and

108

    ●
    The
    competitiveness of the market for the officer’s services.

See
“—2024 Summary Compensation Table.”

Stock
Option Grants

On
January 1, 2023, the Company granted non-qualified stock option to purchase 562,500 of common stock to Saleem Elmasri, CPA, as Chief
Financial Officer, at an exercise price of $1.33 per share.

On
September 29, 2023, the Company granted non-qualified stock options to purchase 710,344 of common stock to Christer Rosén at an
exercise price of $1.33 per share.

On
September 29, 2023, the Company granted non-qualified stock options to purchase 556,673 of common stock to Marshall Hayward at an exercise
price of $1.33 per share.

On
September 29, 2023, the Company granted non-qualified stock options to purchase 81,600 of common stock to Saleem Elmasri, CPA at an exercise
price of $1.33 per share.

On
December 18, 2023, the Company granted non-qualified stock options to purchase 88,909 of common stock to Christer Rosén at an
exercise price of $1.33 per share.

On
December 18, 2023, the Company granted non-qualified stock options to purchase 69,675 of common stock to Marshall Hayward at an exercise
price of $1.33 per share.

On
December 18, 2023, the Company granted non-qualified stock options to purchase 22,320 of common stock to Saleem Elmasri, CPA at an exercise
price of $1.33 per share.

Other
Benefits

In
2024 and 2023, our NEOs were reimbursed for healthcare expenses. The amounts paid to our NEOs in respect of these benefits is reflected
above in “—2024 Summary Compensation Table.”

2023
Equity Incentive Plan

Overview

The
Board of Directors and shareholders holding a majority of the Company’s voting capital approved and adopted